Associate Software Engineer - Full Stack
About the job
- Bachelor’s degree in Computer Science, Engineering, Information Systems, or another STEM field, with 2–4 years of relevant software development experience.
- Hands-on experience through professional work, internships, academic projects, or personal projects in full-stack software development.
- Demonstrated capability in user-interface development using JavaScript or TypeScript, React, HTML5, CSS, NPM, and responsive web-design principles.
- Knowledge of user-interface development practices, including component-based design, cross-browser compatibility, accessibility, and usability.
- Proficiency in Python and SQL, with familiarity with relational and/or NoSQL databases.
- Understanding of RESTful APIs, API integration, and basic data-pipeline concepts.
- Familiarity with cloud services and cloud-native design principles in AWS, Azure, or similar platforms.
- Basic understanding of microservices, containerization, Docker, and Kubernetes.
- Understanding of software development lifecycle practices, version control tools such as Git, and Agile delivery methods.
- Ability to troubleshoot issues, analyze root causes, and escalate complex technical challenges appropriately.
- Strong problem-solving skills with the ability to break down requirements into clear, manageable tasks.
- Ability to document problem statements, technical decisions, and effort estimates clearly.
- Effective verbal and written communication skills.
- Collaborative ability to work effectively with global, cross-functional, and virtual teams.
- Willingness to learn, seek feedback, and adapt to evolving priorities and technologies.
- Ownership and persistence to complete assigned work, even when challenges arise.
- Attention to detail, quality, user experience, and customer or business outcomes.
- Develop and enhance front-end and back-end application components using established engineering standards and guidance from senior team members.
- Develop responsive, accessible, and user-friendly web interfaces using React, TypeScript or JavaScript, HTML5, and CSS.
- Translate user stories, wireframes, and design specifications into high-quality, reusable user-interface components.
- Build reusable front-end components and integrate them with backend APIs, databases, and data services.
- Ensure user-interface solutions are consistent across supported browsers, devices, and screen sizes.
- Build and consume REST APIs, integrate data sources, and support data-processing pipelines.
- Create rapid prototypes to validate technical approaches and translate approved concepts into production-ready code.
- Write clean, reusable, well-documented, secure, and testable code.
- Participate in code reviews and incorporate feedback to improve code quality, performance, accessibility, and maintainability.
- Contribute to unit, integration, user-interface, and automated testing activities.
- Support debugging, root-cause analysis, and resolution of application defects and production issues.
- Assist with application deployment, configuration, and operational support across cloud environments.
- Create and maintain technical documentation, including design notes, API documentation, deployment procedures, and runbooks.
- Work closely with product owners, business stakeholders, user-experience and design teams, data engineers, quality-assurance engineers, and other technology teams.
- Follow Agile practices, contribute to sprint planning and effort estimation, and provide timely status updates.
- Continuously build knowledge of modern full-stack, cloud, artificial-intelligence, and DevOps technologies.
- Exposure to continuous integration and continuous delivery pipelines, DevOps practices, and automated build and deployment tools.
- Familiarity with software design patterns, data structures, test-driven development, and secure coding practices.
- Experience with user-interface testing frameworks such as Jest, React Testing Library, Cypress, or similar tools.
- Familiarity with observability and monitoring tools such as Grafana, Prometheus, or cloud-native monitoring services.
- Experience or interest in developing data, analytics, artificial-intelligence, or generative-artificial-intelligence-enabled applications.
- Familiarity with enterprise architecture principles, authentication and authorization concepts, and API security.
- AWS Certified Developer, AWS Cloud Practitioner, Azure Fundamentals, or equivalent cloud certification.
- SAFe Agile certification or familiarity with Agile frameworks.
- A master’s degree in Computer Science, Engineering, Information Systems, or another STEM field.
- AWS Developer certification.
- Any SAFe Agile certification.
About the company
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $39.4 billion.
- Imdelltra sales jumped 219% year over year in Q1 2026, signaling rapid launch traction.
- Repatha sales rose 37% in Q2 2026, driven by expanding cardiology and primary-care adoption.
What critics are saying
- Prolia and Enbrel face accelerating biosimilar erosion; Amgen expects continued sales declines through 2026.
- Three distributors generated 77% of gross revenue in 2026, concentrating pricing leverage brutally.
- MariTide failure would crater obesity optionality and expose Amgen's growth to aging franchises.
What makes Amgen unique
- September 2026 Imdelltra-IMFINZI phase III hit overall survival in first-line ES-SCLC.
- August 2026 Repatha reduced death risk in high-risk patients, strengthening Amgen's cardiovascular moat.
- MariTide's monthly-or-less dosing and nine Phase III studies separate it from weekly GLP-1s.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.
Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.
Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.
Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.
Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.